New Orleans, Louisiana (ots/PRNewswire) - - Vecima Networks Inc. (TSX: VCM) is launching the EntraTM Interactive Video Controller at the 2019 SCTE·ISBE Cable-Tec Expo in New Orleans, Louisiana. Part of Vecima's Video and Broadband Solutions portfolio of products, the Entra Interactive Video Controller (IVC) is a headend device that provides SCTE 55-2-enabled, set-top ...
New Orleans, Louisiana (ots/PRNewswire) - - Vecima Networks Inc. (TSX:VCM) announced continued innovation in its EntraTM Distributed Access Architecture (DAA) node portfolio today with the addition of support for two Remote PHY Devices (RPDs) in a single node. Vecima, with its highly flexible Entra Access Node for DAA, is able to provide a low barrier to entry today ...
New Orleans, Louisiana (ots/PRNewswire) - - Vecima Networks Inc. (TSX:VCM) announced today it won two 2019 Broadband Technology Report (BTR) Diamond Technology Review awards: one for its MediaScaleX // StorageTM solution and one for its EntraTM Video QAM Manager (VQM). Highly reputable in the cable and telecom industry, the awards are based on a variety of criteria, ...
Vecima Networks Inc.(account designation: Concurrent Computer Corporation); Conway Corporation
Conway Corp to Launch Multi-Viewing, nDVR, Live IP, Start-Over and Catch-Up TV with Vecima's MediaScaleX(TM) Platform New Orleans, Louisiana (ots/PRNewswire) - - Vecima Networks Inc. (TSX:VCM) announced today that Conway Corporation, a North American cable provider, has selected Vecima's MediaScaleX(TM) solution to power its new IPTV multiscreen service. Moving from QAM to IP delivery systems, Conway Corp will be able to ...
issuer: AGRANA Beteiligungs-AG F.-W.-Raiffeisen-Platz 1 A-1020 Wien phone: +43-1-21137-0 FAX: +43-1-21137-12926 mail: info.ab@agrana.com WWW: www.agrana.com ISIN: AT000AGRANA3 indexes: WBI stockmarkets: Wien, Berlin, Stuttgart, Frankfurt language: English ...
New Orleans (ots/PRNewswire) - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the Endocrine Society Annual Meeting in ...
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Placebo[1] - Bempedoic Acid is an ...
New Orleans (ots/PRNewswire) - This material is intended for global medial media only. For journalistic assessment and preparation before publication. Abstract #T-P-3178, oral session #T-OR-2088 US study identified multiple barriers to weight management for people living with obesity Divergent perceptions and attitudes about obesity may jeopardise obesity management ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that Victoza® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts: 293-OR, 240-OR Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 185-OR and 187-OR Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...